Dalotuzumab (MK-0646) is a humanized recombinant monoclonal antibody (IgG1 type) that targets IGF-1R, inhibiting tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation mediated by IGF-1 and IGF-2. It further induces apoptosis and cell cycle arrest. When used alongside other anticancer agents like statins, Dalotuzumab's antitumor activity is significantly enhanced both in vitro and in vivo [1] [2] [3].